July 24, 2025

Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice

The 2025 ASCO Annual Meeting included the presentation of data from more than 7,000 abstracts and clinical trials set to advance research, uncover findings, and in some cases change the standard of pr...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

December 09, 2024

Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit

Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data prese...

The ASCO Post

April 22, 2024

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or ga...

The ASCO Post

May 09, 2024

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric o...

The ASCO Post

June 13, 2023

Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding

Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequent...

The ASCO Post

May 13, 2024

Oral Rinse Could Provide Early Screening for Gastric Cancer

A simple oral rinse may lead to early detection of gastric cancer, according to new findings presented at Digestive Disease Week (DDW) 2024.

The ASCO Post

January 31, 2023

Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study

Initial data from the global phase III SPOTLIGHT trial could herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Fi...

The ASCO Post

June 27, 2025

FDA Approves Pembrolizumab for HER2-Positive Gastric or GEJ Cancer Expressing PD-L1

Traditional approval was granted to the PD-L1 inhibitor with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresecta...

The ASCO Post